Fifth Annual Protein-Protein Interactions Conference Taking Place April 18-19, 2012 in San Diego

Jan. 25, 2012 - PRLog -- CHI's Fifth Annual Protein-Protein Interactions: Targeting PPI for Therapeutic Interventions will be held April 18-19, 2012 in San Diego as part of the Drug Discovery Chemistry conference. Early registration discount ends January 27th.

To view program agenda visit http://www.drugdiscoverychemistry.com/ppi/

In its fifth year, CHI’s conference is covering the journey from identifying PPI interaction pairs all the way to successfully developing a PPI inhibitor. Along the way, many questions need to be answered and obstacles need to be addressed such as challenges the binding sites are presenting, modulation of PPI, predicting PPI modes identifying novel inhibitors and what can be done to target PPI successfully.

Program Agenda:

Keynote Presentation: Chemical Design Principles for the Discovery of Inhibitors of Protein-Protein Interactions
Kim D. Janda, Ph.D., Professor, Departments of Chemistry and Immunology, Ely R. Callaway, Jr. Chair in Chemistry; Director, Worm Institute of Research and Medicine (WIRM); Associate

THERAPEUTIC APPLICATIONS

Targeting FOXM1/NPM Interactions against Cancer
Andrei Gartel, Ph.D., Associate Professor, Medicine, University of Illinois

Cognition Enhancement by Disruption of NR2B-Cdk5 Interactions by a Small Interfering Peptide Drug
James Bibb, Associate Professor, Psychiatry and Neurology

Mimicking the Hotspots at Protein-Protein Interfaces
Lidio Meireles, Ph.D., Scientist, Vertex Pharmaceuticals

Antibody Screening and Characterization Using Multiplexed SPR
Ruben Luo, Ph.D., Product Manager, Bio-Rad Laboratories

Capillary Electrophoresis : an Ideal Solution-Based Method for Monitoring Protein-Protein Interactions
Carol Austin, Ph.D., Biology Group Leader, Selcia

DRUGGABILITY OF PPI

Finding Druggable Hot Spots in Protein–Protein Interfaces
Sandor Vajda, Ph.D., Professor, Biomedical Engineering and Chemistry, Boston University

An Example of Challenging Chemical Space: Protein-Protein Interfaces
Philippe Roche, Ph.D., Senior Scientist, Cancer Research, CNRS

Discovery of the Chromenotriazolopyrimidines: Potent Inbitors of the MDM2-p53 Protein-Protein Interaction
Hilary Plake Beck, Ph.D., Senior Scientist, Amgen, Inc.

Skinning the Cat: Complementary Approaches for Inhibiting PPI and Challenging Enzymes
Michelle Arkin, Ph.D., Associate Adjunct Professor, Pharmaceutical Chemistry; Associate Director

NOVEL TOOLS APPLIED TO PPI

Protein Docking and Conformational Properties of the Interfaces
Ilya Vakser, Ph.D., Director and Professor, Bioinformatics, University of Kansas

ASINEX Approaches to the Protein- Protein Interaction (PPI) Area – From Spiro-Fused Saturated Skeletal Diversity to Peptide Mimetics
Andrea Altieri, Ph.D., Tailored Compound Set Support Manager,ASINEX

A Leap into the Chemical Space of Protein-Protein Interaction Inhibitors
Olivier Sperandio, Ph.D., Senior Research Associate, INSERM

On-Demand Microarray to Study Protein-Protein Interactions
Deb K. Chatterjee, Ph.D., Associate Director & Senior Principal Scientist, Protein Expression

Identification and Characterization of Protein-Protein Interaction Inhibitors
Laura Silvian, Ph.D., Crystallography, Department of Molecular Discovery, Biogen Idec

Substrate-Envelope Approach - A Novel Structure-Based Tool for Design of Highly Specific Drugs for Promiscuous Targets
Moses Prabu, Ph.D., Assistant Professor, Division of Basic Sciences

For more information visit  http://www.drugdiscoverychemistry.com/ppi/

Register by Friday, January 27th to take advantage of the early registration discount. Save up to $300!

# # #

Since 1992, Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.